Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 53 results for "novartis"

Novartis India#39;s board meeting held on November 10, 2017
Money Control

Novartis India#39;s board meeting held on November 10, 2017

We would like to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, November 10, 2017. Money Control, 1 week ago
Novartis India surges 7% as board mulls share buyback Business Standard, 4 weeks ago

16 images for novartis

Money Control, 1 week ago
Money Control, 1 month ago
MSN India, 1 month ago
MSN India, 1 month ago
DNA, 1 month ago
First, 1 month ago
Money Control, 2 months ago
Money Control, 2 months ago
Money Control, 3 months ago
Reuters, 4 months ago

Novartis India to buy back shares worth over Rs 231 cr

Pharma major Novartis India on Monday said that it will buy back shares worth Rs 231.15 crore representing 12.26 per cent of the total paid up equity capital. According to a BSE filing, the company's "Board of Directors" in a meeting held on Monday approved ...
 SME Times3 weeks ago Novartis India board clears share buyback worth Rs 231 cr  Business Standard3 weeks ago Novartis India slips 8% as buyback price disappoints  Business Standard3 weeks ago Novartis India to consider buy back of equity shares  Business Standard4 weeks ago
Money Control

Novartis names drugs chief as CEO to deliver return to growth

ZURICH (Reuters) - Novartis CEO Joe Jimenez will step down on Feb. 1 and hand over to drug development chief Vas Narasimhan to decide the fate of $50 billion in assets and make good on a pledge to return the Swiss company to sales growth.
 Business Standard1 month ago Novartis names Indian-origin Vasant Narasimhan as new CEO  Business Standard1 month ago Indian-origin Vasant Narasimhan to head $48 billion pharma giant Novartis  Business Standard1 month ago Novartis names Indian-origin Vas Narasimhan as Global CEO  Money Control1 month ago

Novartis's Rydapt wins EU approval for AML, other diseases

Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals the medicine secured in April. Rydapt was cleared to be used along ...
 Reuters4 weeks ago Novartis says biosimilar rituximab accepted for review by FDA  Reuters1 month ago Novartis approval for gene therapy signals new cancer treatment era | Reuters  First Post.com1 month ago Novartis gene therapy approval signals new cancer treatment era  Reuters1 month ago
MSN India

Novartis puts Indian doctor from Harvard in charge as CEO

AG on Monday announced the surprise departure of Chief Executive Officer Joseph Jimenez after eight years at the helm of Europe's largest drugmaker, and the appointment of its drug development chief Vasanth Narasimhan as his successor. With this, Jiminez will ...
 MSN India1 month ago Novartis's Jimenez stepping down, Narasimhan named new CEO  Reuters1 month ago
Money Control

Novartis India drops after weak Q1 result

Novartis India lost 2.82% to Rs 641.95 at 09:16 IST on BSE after net profit dropped 63.14% to Rs 7.03 crore on 32.98% decrease in net sales to Rs 114.81 crore in Q1 June 2017 over Q1 June 2016.
 Business Standard2 months ago Novartis India standalone net profit declines 63.14% in the June 2017 quarter  Business Standard2 months ago Novartis India Q1 net profit down 63 pc at Rs 7 cr  Business Standard2 months ago

Novartis says ‍revolade shows long-term disease control for chronic/persistent immune thrombocytopenia​

ZURICH (Reuters) - Novartis said on Wednesday a long term study of ‍its Revolade drug showed good results in treating chronic and persistent immune thrombocytopenia (ITP) - a condition where patients' blood does not clot normally.
 Reuters1 day ago

Novartis' skin cancer drug posts win in trials, Roche flops

Novartis's mix of Tafinlar and Mekinist slashed the risk of melanoma returning or death by 53%
 Business Standard1 month ago Novartis posts a win, Roche a flop in skin cancer trials  Reuters1 month ago

Eli Lilly takes on Pfizer, Novartis with new breast cancer drug data

Eli Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 percent.
 DNA1 month ago Lilly takes on Pfizer, Novartis with new breast cancer drug data  Reuters1 month ago

Novartis' $475,000 cancer breakthrough heralds new era of cures

Novartis's arrangement to pay only if patients respond to the drug as a huge breakthrough
 Business Standard1 month ago Profit on $475,000 Novartis cancer drug could be a while coming  Reuters1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less